Literature DB >> 15001719

Datapoints: Trends in naltrexone use among members of a large private health plan.

Katherine M Harris1, Andrea DeVries, Kelli Dimidjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15001719     DOI： 10.1176/appi.ps.55.3.221

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN： 1075-2730            Impact factor:   3.084


× No keyword cloud information.
  16 in total

1.  Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

Authors:  George E Bigelow; Kenzie L Preston; John Schmittner; Qunming Dong; David R Gastfriend
Journal:  Drug Alcohol Depend       Date:  2011-11-12       Impact factor: 4.492

2.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

3.  Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.

Authors:  Katherine J Karriker-Jaffe; Jianguang Ji; Jan Sundquist; Kenneth S Kendler; Kristina Sundquist
Journal:  Addiction       Date:  2017-05-16       Impact factor: 6.526

4.  The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.

Authors:  Aron N Starosta; Robert F Leeman; Joseph R Volpicelli
Journal:  J Psychiatr Pract       Date:  2006-03       Impact factor: 1.325

5.  First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.

Authors:  Sheryl Spithoff; Suzanne Turner; Tara Gomes; Diana Martins; Samantha Singh
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

Review 6.  A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.

Authors:  Walter Ling
Journal:  J Neuroimmune Pharmacol       Date:  2016-03-23       Impact factor: 4.147

7.  Comparison of healthcare utilization among patients treated with alcoholism medications.

Authors:  Tami L Mark; Leslie B Montejano; Henry R Kranzler; Mady Chalk; David R Gastfriend
Journal:  Am J Manag Care       Date:  2010       Impact factor: 2.229

8.  Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.

Authors:  William C Bryson; John McConnell; P Todd Korthuis; Dennis McCarty
Journal:  Am J Manag Care       Date:  2011-06       Impact factor: 2.229

9.  Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population.

Authors:  Henry R Kranzler; Leslie B Montejano; Judith J Stephenson; Shaohung Wang; David R Gastfriend
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

10.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Authors:  Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.